Polymersomes with LRP-1 Ligands for Amyloid-Beta Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies fail to effectively modulate LRP-1 expression in brain endothelial cells to enhance the clearance of amyloid-β and tau proteins across the blood-brain barrier, which is crucial for treating neurodegenerative disorders like Alzheimer's disease.
Innovation Solution
Synthetic polymer vesicles, or polymersomes, functionalized with LRP-1 ligands are used to promote the transcytosis of LRP-1 across endothelial cells, thereby increasing the clearance of amyloid-β and tau by stabilizing the transport mechanism with syndapin-2, and can be optimized in structure to maximize LRP-1 expression levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If LRP-1 expression is increased in brain endothelial cells to enhance amyloid-β and tau clearance, then clearance efficiency is improved, but current strategies fail to achieve effective modulation
Solution Approach 1:
The patent uses LRP-1 as an intermediary mediator between the polymersomes and the clearance mechanism. The polymersomes bind to LRP-1 on the luminal surface of brain endothelial cells, and this intermediary interaction triggers transcytosis, which subsequently enhances the clearance of amyloid-β and tau proteins across the blood-brain barrier.
Solution Approach 2:
The patent modifies key parameters of the polymersomes including their size (50-500 nm diameter), surface charge, and chemical composition to optimize binding affinity to LRP-1. By adjusting these parameters, the system achieves effective modulation of LRP-1 expression and function, thereby improving clearance efficiency where previous strategies failed.
2Productivity
If polymersomes are designed to bind LRP-1 on endothelial cell surface, then transport of LRP-1 across endothelial cells is promoted, but complexity of nanoparticle design increases
Solution Approach 1:
The polymersome structure is segmented into distinct functional components: a polymeric backbone providing structural integrity, surface-functionalized ligands for LRP-1 binding, and an encapsulated therapeutic payload. This segmentation allows each component to be optimized independently while working together to achieve efficient LRP-1 transport.
Solution Approach 2:
The polymersomes are designed as multi-functional nanocarriers that simultaneously: (1) bind to LRP-1 receptors, (2) induce transcytosis across endothelial cells, (3) deliver encapsulated drugs to the brain, and (4) clear amyloid-β and tau proteins. This multi-functionality reduces the need for separate therapeutic agents and simplifies the overall treatment approach.
3Productivity
If LRP-1-mediated clearance is enhanced to reduce amyloid-β and tau levels, then therapeutic effect is improved, but degradation of LRP-1 may occur without proper stabilization
Solution Approach 1:
The patent employs syndapin-2, a protein that stabilizes LRP-1, to protect the receptor from degradation before it can be effectively utilized for clearance. This prior cushioning ensures that LRP-1 remains stable and functional throughout the transcytosis process, preventing its degradation and maintaining its ability to mediate amyloid-β and tau clearance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of polymersomes with LRP-1 ligands significantly enhances the basal to apical transport of amyloid-β and tau, reducing their levels in the brain and offering a therapeutic approach for neurodegenerative diseases by improving LRP-1-mediated clearance.
Implementation Method 1
the nanoparticle or microparticle comprises a ligand type on its external surface which is capable of binding to low density lipoprotein receptor-related protein 1 (LRP-1) on said endothelial cell surface
Implementation Method 2
thereby promoting transport of LRP-1 across said endothelial cell... LRP-1 which has undergone endocytosis can then be trafficked across the endothelial cell via an endolysosomal network, and can subsequently be presented via exocytosis onto the opposite side of the plasma membrane to its original position. This whole process is known as transcytosis.
Data Source
AI summary
The present invention is directed to a nanoparticle or microparticle for binding to the surface of an endothelial cell, e.g. a brain endothelial cell, for use in a method for reducing amyloid-β and/or tau levels in an organ (e.g. the brain) of a patient in need thereof, wherein the nanoparticle or microparticle comprises a ligand type on its external surface which is capable of binding to low density lipoprotein receptor-related protein 1 (LRP-1) on said endothelial cell surface, thereby promoting transport of LRP-1 across said endothelial cell. The present invention is further directed to such nanoparticles or microparticles per se which additionally comprise an encapsulated drug selected from an anti-Alzheimer's drug and/or a drug that is useful in reducing amyloid-β and/or tau levels or inhibiting amyloid-β and/or tau formation, and pharmaceutical compositions comprising a plurality of such nanoparticles or microparticles.